English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS


Rigel Pharmaceuticals (Nasdaq: RIGL) announced that the FDA has granted Fast Track designation to R289 for treating patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289, a dual inhibitor of IRAK1 and IRAK4, is currently being evaluated in a Phase 1b study. The Fast Track designation may provide benefits including more frequent FDA interactions and eligibility for Accelerated Approval and Priority Review. The drug works by blocking inflammatory cytokine production in response to toll-like receptor and interleukin-1 receptor family signaling, targeting the pro-inflammatory environment in bone marrow responsible for persistent cytopenias in lower-risk MDS patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
12K Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    6653
    Followers
    44
    Following
    72K
    Visitors
    Follow
    Discussing
    Trump 2.0 countdown: What's the next big opportunity in the markets?
    🎙️️ Discussion: 1. Could Trump's cryptocurrency policies potentially benefit the crypto market? 2. Might his tariff policies have a positiv Show More